Kodiak Sciences (KOD) Receives a Sell from Barclays

Barclays analyst Gena Wang maintained a Sell rating on Kodiak Sciences (KOD – Research Report) today and set a price target of $3.00. The company’s shares closed yesterday at $3.74.

According to TipRanks, Wang is a 4-star analyst with an average return of 9.3% and a 46.19% success rate. Wang covers the Healthcare sector, focusing on stocks such as Legend Biotech, Vertex Pharmaceuticals, and Sarepta Therapeutics.

Kodiak Sciences has an analyst consensus of Moderate Sell, with a price target consensus of $5.00.

Based on Kodiak Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $59.52 million. In comparison, last year the company had a GAAP net loss of $70.45 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kodiak Sciences (KOD) Company Description:

Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.